217 related articles for article (PubMed ID: 16785827)
41. Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition.
Frölich S; Olliges A; Kern N; Schreiber Y; Narumiya S; Nüsing RM
Am J Physiol Renal Physiol; 2012 Jul; 303(2):F209-19. PubMed ID: 22573380
[TBL] [Abstract][Full Text] [Related]
42. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
Amer M; Bead VR; Bathon J; Blumenthal RS; Edwards DN
Cardiol Rev; 2010; 18(4):204-12. PubMed ID: 20539104
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
[TBL] [Abstract][Full Text] [Related]
44. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
Swan SK; Rudy DW; Lasseter KC; Ryan CF; Buechel KL; Lambrecht LJ; Pinto MB; Dilzer SC; Obrda O; Sundblad KJ; Gumbs CP; Ebel DL; Quan H; Larson PJ; Schwartz JI; Musliner TA; Gertz BJ; Brater DC; Yao SL
Ann Intern Med; 2000 Jul; 133(1):1-9. PubMed ID: 10877734
[TBL] [Abstract][Full Text] [Related]
45. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.
Bosch-Marcè M; Clària J; Titos E; Masferrer JL; Altuna R; Poo JL; Jiménez W; Arroyo V; Rivera F; Rodés J
Gastroenterology; 1999 May; 116(5):1167-75. PubMed ID: 10220509
[TBL] [Abstract][Full Text] [Related]
46. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process.
Vuolteenaho K; Moilanen T; Moilanen E
Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):10-4. PubMed ID: 17973900
[TBL] [Abstract][Full Text] [Related]
47. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors.
Sandhu GK; Heyneman CA
Ann Pharmacother; 2004 Apr; 38(4):700-4. PubMed ID: 14982980
[TBL] [Abstract][Full Text] [Related]
48. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
49. COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys.
Matzdorf C; Kurtz A; Höcherl K
Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1782-90. PubMed ID: 17376760
[TBL] [Abstract][Full Text] [Related]
50. [Recent development of selective cyclooxygenase-2 inhibitors].
Kawai S
Nihon Rinsho; 2002 Dec; 60(12):2370-7. PubMed ID: 12510364
[TBL] [Abstract][Full Text] [Related]
51. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
[TBL] [Abstract][Full Text] [Related]
52. Localization of cyclooxygenase-2 in mice vas deferens and its effects on fertility upon suppression using nimesulide: a preferential cyclooxygenase-2 inhibitor.
Balaji T; Ramanathan M; Menon VP
Toxicology; 2007 May; 234(1-2):135-44. PubMed ID: 17382448
[TBL] [Abstract][Full Text] [Related]
53. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
Bruno A; Tacconelli S; Patrignani P
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
[TBL] [Abstract][Full Text] [Related]
54. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause male-biased sex differentiation in zebrafish.
Bereketoglu C; Pradhan A; Olsson PE
Aquat Toxicol; 2020 Jun; 223():105476. PubMed ID: 32315829
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
Jones MK; Wang H; Peskar BM; Levin E; Itani RM; Sarfeh IJ; Tarnawski AS
Nat Med; 1999 Dec; 5(12):1418-23. PubMed ID: 10581086
[TBL] [Abstract][Full Text] [Related]
56. An update on cyclooxygenase-2 expression and metabolites in the kidney.
Harris RC
Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):64-9. PubMed ID: 18090672
[TBL] [Abstract][Full Text] [Related]
57. Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition.
Athirakul K; Kim HS; Audoly LP; Smithies O; Coffman TM
Kidney Int; 2001 Dec; 60(6):2324-9. PubMed ID: 11737606
[TBL] [Abstract][Full Text] [Related]
58. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease.
Ruan CH; So SP; Ruan KH
Life Sci; 2011 Jan; 88(1-2):24-30. PubMed ID: 21035466
[TBL] [Abstract][Full Text] [Related]
59. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage.
Tanaka A; Hase S; Miyazawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Mar; 300(3):754-61. PubMed ID: 11861778
[TBL] [Abstract][Full Text] [Related]
60. Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs.
Ković SV; Vujović KS; Srebro D; Medić B; Ilic-Mostic T
Curr Med Chem; 2016; 23(19):1953-64. PubMed ID: 26861001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
